Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 99
Filter
1.
Med. infant ; 30(2): 114-121, Junio 2023. Ilus, tab
Article in Spanish | LILACS, UNISALUD, BINACIS | ID: biblio-1443459

ABSTRACT

Las Leucemias y linfomas constituyen las enfermedades oncológicas más frecuentes en pediatría y las bacteriemias representan infecciones graves en estos pacientes. Objetivos: describir los microorganismos aislados de sangre en pacientes con leucemia aguda o linfoma pediátrico; comparar la incidencia de aislamientos según enfermedad de base; detallar las variaciones en la incidencia de dichos aislamientos y la evolución de su resistencia antimicrobiana. Estudio retrospectivo, observacional. Se incluyeron 823 episodios de bacteriemia en 467 pacientes pediátricos, entre julio-2016 y junio-2022, dividido en tres períodos (período-1: años 2016- 2018, período-2: años 2018-2020, período-3: años 2020-2022). Se aislaron 880 microorganismos: 55,3% gram negativos (GN), 40% gram positivos (GP) y 4,7% levaduras. En GN predominaron: enterobacterias (72%) y en GP: estreptococos del grupo viridans (SGV) (34,1%). Se encontró asociación entre LLA-enterobacterias (p=0,009) y LMA-SGV (p<0,001). Hubo aumento de GN entre los períodos 1 y 3 (p=0,02) y 2 y 3 (p=0,002) y disminución de GP entre 2 y 3 (p=0,01). Se registraron los siguientes mecanismos de resistencia: BLEE (16,4%), carbapenemasas: KPC (2,5%); MBL (2,7%) y OXA (0,2%); meticilinorresistencia en Staphylococcus aureus (20%) y estafilococos coagulasa negativos (95%), vancomicina resistencia en Enterococcus spp. (39%), SGV no sensibles a penicilina (44%) y a cefotaxima (13%). Hubo aumento de MBL entre los períodos 1 y 2 (p=0,02) y una tendencia en disminución de sensibilidad a penicilina en SGV entre el 1 y 3 (p=0,058). El conocimiento dinámico y análisis de estos datos es esencial para generar estadísticas a nivel local, fundamentales para el diseño de guías de tratamientos empíricos (AU)


Leukemias and lymphomas are the most common cancers in children and bacteremia is a severe infection in these patients. Objectives: to describe the microorganisms isolated from blood in pediatric patients with acute leukemia or lymphoma; to compare the incidence of isolates according to the underlying disease; and to detail the variations in the incidence of these isolates and the evolution of their antimicrobial resistance. Retrospective, observational study. We included 823 episodes of bacteremia in 467 pediatric patients seen between July-2016 and June-2022, divided into three periods (period-1: 2016- 2018, period-2: 2018-2020, period-3: 2020-2022). A total of 880 microorganisms were isolated: 55.3% were gram-negative (GN), 40% gram-positive (GP) and 4.7% yeasts. In GN there was a predominance of: enterobacteria (72%) and in GP viridans group streptococci (VGS) (34.1%). An association was found between ALL-enterobacteria (p=0.009) and AML-VGS (p<0.001). There was an increase in GN between periods 1 and 3 (p=0.02) and 2 and 3 (p=0.002) and a decrease in GP between 2 and 3 (p=0.01). The following resistance mechanisms were recorded: BLEE (16.4%), carbapenemases: KPC (2.5%), MBL (2.7%), and OXA (0.2%); methicillin resistance in Staphylococcus aureus (20%) and coagulase negative staphylococci (95%), vancomycin resistance in Enterococcus spp. (39%), VGS resistant to penicillin (44%) and to cefotaxime (13%). There was an increase in MBL between periods 1 and 2 (p=0.02) and a decreasing trend in penicillin sensitivity in VGS between periods 1 and 3 (p=0.058). Dynamic knowledge and analysis of these data is essential to generate statistics at the local level, which is fundamental for the design of empirical treatment guidelines (AU)


Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Leukemia, Myeloid, Acute/complications , Leukemia, Lymphoid/complications , Follow-Up Studies , Bacteremia/microbiology , Febrile Neutropenia/etiology , Lymphoma/complications , Acute Disease , Retrospective Studies , Cohort Studies , Drug Resistance, Bacterial , Anti-Infective Agents/adverse effects
2.
Journal of Experimental Hematology ; (6): 389-395, 2023.
Article in Chinese | WPRIM | ID: wpr-982071

ABSTRACT

OBJECTIVE@#To explore the risk and location of multiple malignancies in patients with hematologic malignancies who were followed up for 9 years in Jiangsu Province Hospital and to evaluate the impact of the second primary malignancy on survival of patients.@*METHODS@#The incidence and survival of multiple malignancies in 7 921 patients with hematologic malignancies from 2009 to 2017 were analyzed retrospectively.@*RESULTS@#A total of 180 (2.3%, 180/7 921) patients developed second malignancy, of whom 58 patients were diagnosed with hematologic malignancies as the first primary malignancy, and 98 patients developed hematologic malignancies as second primary malignancy, and the other 24 cases were diagnosed with the second malignancy within 6 months after the first primary malignancy was diagnosed, which was difined as multiple malignancies occurring simultaneously. In 180 patients, 18 cases developed two hematologic malignancies successively, and 11 patients developed more than 3 primary cancers (among them, 2 female patients were diagnosed with 4 primary cancers). Patients with lymphoma and multiple myeloma (MM) as the second primary malignancy had poorer survival than patients with lymphoma and MM as the first primary malignancy. Patients with chronic myeloid leukemia as the second primary malignancy were also associated with inferior overall survival.@*CONCLUSION@#In this study, 2.3% of hematologic malignancy patients had multiple mali-gnancies, lymphoma and MM as the second primary malignancy had poor survival.


Subject(s)
Humans , East Asian People , Hematologic Neoplasms/complications , Lymphoma/complications , Multiple Myeloma/complications , Neoplasms, Second Primary , Retrospective Studies , Survival Analysis
3.
Acta méd. costarric ; 63(3)sept. 2021.
Article in Spanish | LILACS, SaludCR | ID: biblio-1383376

ABSTRACT

Resumen Bordetella bronchiseptica es un cocobacilo Gram negativo patógeno de animales que, con poca frecuencia causa infecciones en seres humanos. La mayoría de casos registrados en la literatura están asociados con pacientes que presentan algún tipo de inmunosupresión. Este reporte de caso se refiere a una paciente femenina de 67 años con antecedentes de linfoma pulmonar, que recibió quimioterapia y radioterapia 16 años atrás, fue ingresada al Servicio de Medicina Interna del Hospital Tomás Casas Casajús con un diagnóstico de neumonía bacteriana, tras descartarse infección por Covid19. Unos días después, se aisló una B. brochiseptica de una muestra de esputo y con el reporte de la prueba sensibilidad a los antibióticos, se modificó la terapia de antibióticos que originalmente se había indicado, lo que se conlleva a una mejoría en el estado físico de la paciente. Sin embargo, debido a una aparente infección nosocomial la paciente se contagió de SARS- CO2 y falleció debido a las complicaciones causadas por el Covid19.


Abstract Bordetella bronchiseptica is an animal pathogenic Gram negative coccobacillus that infrequently causes human infections. Most of the cases recorded in the literature are associated with patients with some type of immunosuppression. In this case, a 67-year- old female patient with a history of pulmonary lymphoma, who received chemotherapy and radiotherapy 16 years ago, is admitted to the Internal Medicine Service of the Tomás Casas Casajús Hospital, with a diagnosis of bacterial pneumonia, after ruling out Covid19 infection. A few days later, a B. brochiseptica is isolated from a sputum sample and with the report of the antibiotic sensitivity test, the antibiotic therapy that had originally been indicated is modified, which is reflected in an improvement in the physical state of the patient. However, due to an apparent nosocomial infection, the patient becomes infected with SARS-CO2 and dies due to complications caused by Covid19.


Subject(s)
Humans , Female , Aged , Bordetella Infections/diagnostic imaging , Lymphoma/complications , Costa Rica
5.
Rev. bras. ciênc. saúde ; 24(3): 465-474, set. 25, 2020. tab
Article in Portuguese | LILACS, ColecionaSUS, CONASS, SES-MA | ID: biblio-1179431

ABSTRACT

Objetivo: Avaliar o perfil nutricional de pacientes onco-hematológicos internados em um hospital especializado em câncer em São Luís - MA. Metodologia: Estudo transversal, retrospectivo, analítico, com coleta de dados secundária, envolvendo pacientes com idade mínima de 18 anos, de ambos os gêneros e que tenham sido submetidos a pelo menos uma ASG-PPP (Avaliação Subjetiva Global Produzida Pelo Paciente). Os dados foram coletados em registros do Serviço de Nutrição e Dietética do hospital. Analisaram-se dados demográficos (gênero e idade), clínicos (diagnóstico) e nutricionais: Índice de massa corporal (IMC), circunferên-cia braquial (CB), prega cutânea tricipital (PCT), circunferência muscular do braço (CMB) e ASG-PPP. As análises foram realizadas no programa estatístico Stata® 13.0. O nível de significância utilizado para os testes foi de p<0,05. Resultados: Foram avaliados 330 pacientes, onde foi constatado que 67,58% eram de adultos e 32,42% de idosos, com maior frequência do sexo masculino, com 60,30%. Ocorreu maior incidência de leucemia (58,48%), seguidos de linfomas (24,85%), mieloma múltiplo (13,33%) e síndrome mielodisplásica (3,3%). Na avaliação do estado nutricional os resultados mostraram que a ASG-PPP detectou maior número de pacientes com algum grau de desnutrição do que outros indicadores (93,94%), seguido pela PCT (65,76%), CMB (53,64%), CB (45,45%) e IMC (14,87%). De acordo com o IMC, foi encontrado maior incidência de eutrofia, correspondendo a 57,27% da amostra. Conclu-são: Diante do que foi encontrado, destaca-se que a desnutrição é um aspecto de extrema importância a ser considerado no tratamento de pacientes onco-hematológicos, visto que pode interferir diretamente no prognóstico da doença. (AU)


Objective: To evaluate the nutritional profile of onco-hematological patients admitted to a specialized cancer hospital in São Luís - MA. Methodology: Cross-sectional, retrospective, analytical study, with secondary data collection, involving patients aged at least 18 years, of both genders and having undergone at least one ASG-PPP (Subjective Global Assessment Produced by the Patient). Data were collected from records of the Hospital's Nutrition and Dietetics Service. Demographic (gender and age), clinical (diagnostic) and nutritional: Body Mass Index (BMI), Brachial Circumference (CB), Tricipital Skinfold (PCT), Muscular Arm Circumference (CMB) and ASG-PPP data were analyzed. The analyses were performed using the Stata® 13.0 statistical program. The level of significance used for the tests was p<0.05. Results: 330 patients were evaluated, in which it was found that 67.58% are adults and 32.42% are elderly, with a higher frequency of males with 60.30%. There was a higher incidence of Leukemia (58.48%), followed by Lymphomas (24.85%), Multiple Myeloma (13.33%) and Myelodysplastic Syndrome (3.3%). In the assessment of nutritional status, the results showed that ASG-PPP detected a greater number of patients with some degree of malnutrition than other indicators (93.94%), followed by PCT (65.76%), CMB (53.64%), CB (45.45%) and BMI (14.87%). According to the BMI, a higher incidence of eutrophy was found, which corresponds to 57.27% of the sample. Conclusion: In view of what was found, it is highlighted that malnutrition is an extremely important aspect to be considered in the treatment of onco-hematological patients, since it can directly interfere in the prognosis of the disease. (AU)


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Myelodysplastic Syndromes/complications , Leukemia/complications , Nutritional Status , Malnutrition/etiology , Lymphoma/complications , Cross-Sectional Studies , Retrospective Studies
6.
Med. infant ; 26(1): 19-26, Marzo 2019. tab, ilus
Article in Spanish | LILACS | ID: biblio-994720

ABSTRACT

Introducción: Para predecir una infección en estadios tempranos en niños con cáncer se han evaluado marcadores como ESD, PCR y PCT. Objetivo: evaluar la precisión diagnóstica para bacteriemia de estos marcadores al ingreso en niños con fiebre y leucemia aguda (LA) o linfoma (L) internados entre 2013-2016. Métodos: estudio analítico retrospectivo. Revisión de historias clínicas. Se calcularon sensibilidad, especificidad, valor predictivo positivo, valor predictivo negativo y área bajo la curva ROC para cada marcador en MedCalc® V16.8.4. Se obtuvo autorización del Comité de Ética. Resultados:en total se internaron 31 niños con diagnóstico de LA y L, 19 presentaron fiebre y 12 no. Hubo 40 episodios de fiebre clasificados en 4 grupos: bacteriemia 14 (35%), infección documentada microbiológicamente 5 (12.5%), infección documentada clínicamente 2 (5%) y fiebre de origen desconocido 19 (47.5%). Los niveles de PCT fueron mayores en el grupo de bacteriemia registrando un valor promedio de 1,17ng/ mL (p: 0.045). El área bajo la curva ROC entre el grupo con y sin bacteriemia fue de 0.50 para ESD, 0.65 para PCR y 0.83 para PCT con S de 77.78%, E de 66.67%, VPP de 50% y VPN de 92.86%. Discusión: la PCT mostró ser el más eficaz que ESD y PCR para predecir bacteriemia. se deben realizar investigaciones con biomarcadores con el objeto de disminuir el uso inadecuado de antibióticos en pacientes con fiebre secundaria a enfermedad y acortar los tiempos de tratamiento en pacientes con infecciones adecuadamente resueltas mejorando ampliamente la calidad de vida en niños con cáncer (AU)


Introduction: To predict infection in early stages in children with cancer, markers such as ESR, CRP, and PCT have been evaluated. Objective: To evaluate the diagnostic precision for bacteremia of these markers on admission of children with fever and acute leukemia (AL) or lymphoma (L) admitted between 2013- 2016. Methods: A retrospective analytical study. Review of the clinical records. Sensitivity, specificity, positive predictive value, negative predictive value, and area under the ROC curve were calculated for each marker in MedCalc® V16.8.4. The study was approved by the Ethics Committee. Results: Overall, 31 children with AL and L were admitted, 19 of whom presented with fever and 12 did not. There were 40 episodes of fever classified into 4 groups: bacteremia 14 (35%), microbiologically documented infection 5 (12.5%), clinically documented infection 2 (5%), and fever of unknown etiology 19 (47.5%). PCT levels were higher in the group with bacteremia with a mean value of 1.17ng/mL (p:0.045). The area under the ROC curve between the groups with and without bacteremia was 0.50 for ESR, 0.65 for CRP, and 0.83 for PCT with a sensitivity of 77.78%, specificity of 66.67%, PPV of 50%, and NPV of 92.86%. Discussion: PCT showed a greater efficacy than ESD and CRP to predict bacteremia. Research on biomarkers should be conducted to reduce the inadequate use of antibiotics in patients with fever secondary to disease and to shorten treatment times in patients with adequately resolved infections, thereby improving quality of life in children with cancer (AU)


Subject(s)
Humans , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Blood Sedimentation , Leukemia/complications , Polymerase Chain Reaction/methods , Bacteremia/diagnosis , Fever/complications , Lymphoma/complications , Acute Disease , Retrospective Studies , Risk Factors , Bacteremia/microbiology
7.
Clinics ; 73(supl.1): e412s, 2018. tab, graf
Article in English | LILACS | ID: biblio-952843

ABSTRACT

Type 2 diabetes mellitus and cancer are correlated with changes in insulin signaling, a pathway that is frequently upregulated in neoplastic tissue but impaired in tissues that are classically targeted by insulin in type 2 diabetes mellitus. Many antidiabetes treatments, particularly metformin, enhance insulin signaling, but this pathway can be inhibited by specific cancer treatments. The modulation of cancer growth by metformin and of insulin sensitivity by anticancer drugs is so common that this phenomenon is being studied in hundreds of clinical trials on cancer. Many meta-analyses have consistently shown a moderate but direct effect of body mass index on the incidence of multiple myeloma and lymphoma and the elevated risk of leukemia in adults. Moreover, new epidemiological and preclinical studies indicate metformin as a therapeutic agent in patients with leukemia, lymphomas, and multiple myeloma. In this article, we review current findings on the anticancer activities of metformin and the underlying mechanisms from preclinical and ongoing studies in hematologic malignancies.


Subject(s)
Humans , Plasmacytoma/drug therapy , Leukemia/drug therapy , Diabetes Mellitus, Type 2/drug therapy , Hypoglycemic Agents/therapeutic use , Lymphoma/drug therapy , Metformin/therapeutic use , Plasmacytoma/complications , Leukemia/complications , Body Mass Index , Risk Factors , Diabetes Mellitus, Type 2/complications , Hypoglycemic Agents/adverse effects , Insulin , Lymphoma/complications , Metformin/adverse effects
8.
Rev. bras. reumatol ; 57(2): 174-181, Mar.-Apr. 2017. tab, graf
Article in English | LILACS | ID: biblio-844226

ABSTRACT

Abstract Juvenile rheumatic diseases affect the musculoskeletal system and begin before the age of 18. These conditions have varied, identifiable or unknown etiologies, but those of an autoimmune inflammatory nature have been associated with an increased risk of development of cancer, regardless of treatment. This study aims to assess, through a systematic review of the literature according to Prisma (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) quality criteria, the risk of cancer in patients with juvenile rheumatic disease, and its association with biological agents. The criteria described by the Strengthening the Reporting of Observational Studies in Epidemiology initiative were used in order to assess the methodological quality of those individual items selected in this study. We analyzed nine publications, from a total of 251 papers initially selected. There was an increase in cancer risk in the population with juvenile rheumatic disease versus the general population. Most specified cancers were of a lymphoproliferative nature. Seven studies did not specify the treatment or not defined an association between treatment and cancer risk. Only one study has suggested this association; in it, their authors observed high risk in patients diagnosed in the last 20 years, a period of the advent of new therapies. One study found an increased risk in a population not treated with biological agents, suggesting a disease in its natural course, and not an adverse effect of therapy. Studies have shown an increased risk of malignancy associated with juvenile rheumatic disease, and this may be related to disease activity and not specifically to the treatment with biological agents.


Resumo As doenças reumáticas juvenis afetam o sistema musculoesquelético e se iniciam antes dos 18 anos. Apresentam etiologia variada, identificável ou desconhecida, porém as de natureza inflamatória autoimune têm sido associadas ao maior risco de desenvolvimento de neoplasias, independentemente do tratamento. Este artigo propõe avaliar, por meio de revisão sistemática da literatura de acordo com os critérios de qualidade Prisma (Preferred Reporting Items for Systematic Reviews and Meta- Analyses), o risco de câncer em pacientes com doenças reumáticas juvenis e sua associação com imunobiológicos. Os critérios descritos pela iniciativa Strengthening the Reporting of Observational Studies in Epidemiology foram usados para avaliar a qualidade metodológica individual dos artigos selecionados no presente estudo. Foram analisadas nove publicações, de 251 incialmente selecionadas. Houve aumento no risco de câncer na população com doença reumática juvenil comparada com a população em geral. A maioria dos cânceres especificados foi de natureza linfoproliferativa. Sete estudos não especificaram a terapêutica ou não definiram associação entre ela e o risco de câncer. Apenas um estudo sugeriu essa associação e observou maior risco em pacientes diagnosticados nos últimos 20 anos, período de advento de novas terapias. Um estudo constatou maior risco em uma população não tratada com imunobiológicos, sugeriu tratar-se da evolução natural da doença, e não do efeito adverso da terapêutica. Os estudos demonstram aumento no risco de malignidade associada a doenças reumáticas juvenis que pode estar relacionada à atividade da doença, e não especificamente ao tratamento com imunobiológicos.


Subject(s)
Humans , Child , Autoimmune Diseases/complications , Autoimmune Diseases/drug therapy , Biological Therapy , Rheumatic Diseases/complications , Rheumatic Diseases/drug therapy , Lymphoproliferative Disorders/complications , Lymphoproliferative Disorders/pathology , Autoimmune Diseases/pathology , Rheumatic Diseases/pathology , Lymphoma/complications , Lymphoma/pathology , Lymphoma/drug therapy , Lymphoproliferative Disorders/drug therapy
9.
Medicina (B.Aires) ; 77(1): 17-23, feb. 2017. ilus, tab
Article in Spanish | LILACS | ID: biblio-841627

ABSTRACT

Los linfomas primarios del sistema nervioso central (LPSNC) son neoplasias infrecuentes confinadas al SNC. Más del 90% son de tipo B y afectan principalmente a pacientes entre 50-70 años. La inmunodeficiencia es el factor de riesgo más importante. El objetivo de nuestro trabajo fue evaluar las características demográficas, estado inmunológico y los hallazgos en los estudios complementarios de pacientes con LPSNC. Se realizó el análisis retrospectivo de 48 casos estudiados en nuestro centro desde enero 1992 a mayo 2015. La edad mediana de presentación fue 61 años (25-84); la relación hombre:mujer 2.1:1. El 85% (41 casos) fueron inmunocompetentes al momento del diagnóstico. El 94% (45 casos) tuvo compromiso parenquimatoso, 4% (2 casos) meníngeo y 2% (1 caso) ocular. El lóbulo más afectado fue el frontal (43%) y 35% tuvieron compromiso ganglio basal. En RM, el 89% mostró realce con contraste y 55% restricción en difusión. El síndrome piramidal fue la manifestación inicial más frecuente (56%). El LCR fue inflamatorio en el 72%, aunque solo 11.1% presentó examen citológico positivo. El tipo más frecuente de LPSNC fue no-Hodgkin B (96%) y el subtipo difuso de células grandes el más habitual (83%). En nuestra serie la ausencia de inmunocompromiso fue una característica frecuente y la presentación clínico-radiológica fue muy pleomórfica. La sospecha inicial permitiría arribar a un diagnóstico temprano, evitando tratamientos empíricos que puedan confundir o retrasar el diagnóstico.


Primary central nervous system lymphoma (PCNSL) is an infrequent form of non-Hodgkin lymphoma restricted to the CNS. More than 90% are type B and mainly affect patients aged 50-70 years. Immunodeficiency is the most important risk factor. The aim of our study was to evaluate the immune status, clinical presentation and findings in complementary studies of PCNSL patients. A retrospective analysis of 48 cases treated in our center between January 1992 and May 2015 was performed. Median age at diagnosis was 61 years (range 25-84); with male predominance (2.1:1). Forty one cases (85%) were immunocompetent patients. Brain MRI findings showed parenchymal involvement in 45 cases (94%), 43% with frontal lobe and 35% basal ganglia, 4% had meningeal involvement and 2% had ophthalmic involvement at diagnosis. Fifty-five percent had restricted signal on diffusion weighted imaging and contrast enhancement was found in 89%. Pyramidal syndrome was the main initial clinical manifestation (56%). There were abnormal findings in 62% of CSF samples, but in only 11.1% positive cytology results were detected. The most frequent type was diffuse large B-cell lymphoma (83%), being B-cell type the most common form between them (96%). In our series PCNSL was more frequent in immunocompetent elderly male subjects. At initial evaluation, clinical manifestations and MRI findings were variable. The initial suspicion of this entity would allow an early diagnosis, avoiding empirical treatments that may confuse or delay diagnosis.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Central Nervous System Neoplasms/complications , Central Nervous System Neoplasms/diagnosis , Central Nervous System Neoplasms/immunology , Lymphoma/complications , Lymphoma/diagnosis , Lymphoma/immunology , Biopsy , Magnetic Resonance Imaging , Retrospective Studies , Sex Distribution
10.
Lima; s.n; ene. 2017.
Non-conventional in Spanish | LILACS, BRISA | ID: biblio-847652

ABSTRACT

INTRODUCCIÓN: Antecedentes: El present dictamen expone la evaluación de tecnología de l eficacia y seguridad de brentuximab vedotin en el tratamiento de pacientes con linfoma anaplásico de células T sistémico ALK negativo con progresión de enfermedad a más de 2 líneas de quimioterapia. Aspectos Generales: El linfoma anaplásico de células grandes (ALCL por "anaplastic large cell lymphoma") es un tipo rato, agresivo y heterogéneo no Hodgkin (LNH) de células T con expresion CD30 en las células tumorales. El ALCL constiuye aproximadamente el 2-3% de todos los LNH y menos del 15% de todos los linfomas periférico de células T. Tecnologia Sanitaria de Interés: Brentuximab vedotin es un conjugado de anticuerpo-medicamento que consiste en tres componentes: (i) el anticuerpo quimérico IgG1 cAC10 específico para CD30 jumano; (ii) el agente bloqueador de microtúbulos MMAE (monomethyl auristatin E); y (iii) un proteasa separable que une covalentemente el MMAE AL Cac10 (11). METODOLOGÍA: Estrategia de Búsqueda: Se realizó una búsqueda de la literatura con respecto a la eficacia y seguridad de brentuximab vedotin como tratamiento de pacientes con diagnóstico de linforma anaplásico de celulas T, ALK negativo, con progressión de enfermedad a más de 2 líneas de quimioterapia. Eseta búsqueda se realizó utilizando los meta-buscadores: Translating Research into Practice (TRIPDATABASE), National Library of Medicine (Pubmed-Medline) y Helath System Evidence. RESULTADOS: Sinopsis de la Evidencia: Se realizó la búsqueda bibliográfica y de la evidencia cientifica para el sustento del uso de brentuximab vedotin como tratamiento de pacientes con diagnóstico de linfoma anaplásico de célulaas T, ALK negativo, con progressión de enfermedad a más de 2 líneas de quimioterapia. Se presenta la evidencia disponbible según el tipo de publicación en los criterios de inclusión. CONCLUSIONES: Brentuximab vedotin ha sido evaluado en un solo ensayo pequeño, abierto de fase II y sin grupo comparador. El objetivo primario fue determinar la eficacia antineoplásica del agente vedotn (1.8 mg/kg vía E.V cada 3 semanas) en términos de la tasa de respuesta objetiva (TRO) . De manera secundaria se midieron los desenlaces de tiempo hasta a evento como la SG y la SLP. El Instituto de Evaluación de Tecnologías en Salud e Investigación IETSI, no aprueba el uso de brentuximab vedotin para el tratamiento de pacientes con ALCLs, ALK negativo y con progressión a > = 2 líneas de quimioterapia.


Subject(s)
Humans , Lymphoma/complications , Lymphoma/drug therapy , Antineoplastic Agents/administration & dosage , Chemotherapy, Adjuvant , Technology Assessment, Biomedical , Treatment Outcome
12.
Einstein (Säo Paulo) ; 13(4): 500-505, Oct.-Dec. 2015. tab, graf
Article in Portuguese | LILACS | ID: lil-770508

ABSTRACT

ABSTRACT Objective To characterize the pattern of primary small bowel cancers in a tertiary East-European hospital. Methods A retrospective study of patients with small bowel cancers admitted to a tertiary emergency center, over the past 15 years. Results There were 57 patients with small bowel cancer, representing 0.039% of admissions and 0.059% of laparotomies. There were 37 (64.9%) men, mean age of 58 years; and 72 years for females. Out of 57 patients, 48 (84.2%) were admitted due to an emergency situation: obstruction in 21 (38.9%), perforation in 17 (31.5%), upper gastrointestinal bleeding in 8 (14.8%), and lower gastrointestinal bleeding in 2 (3.7%). There were 10 (17.5%) duodenal tumors, 21 (36.8%) jejunal tumors and 26 (45.6%) ileal tumors. The most frequent neoplasms were gastrointestinal stromal tumor in 24 patients (42.1%), adenocarcinoma in 19 (33.3%), lymphoma in 8 (14%), and carcinoids in 2 (3.5%). The prevalence of duodenal adenocarcinoma was 14.55 times greater than that of the small bowel, and the prevalence of duodenal stromal tumors was 1.818 time greater than that of the small bowel. Obstruction was the complication in adenocarcinoma in 57.9% of cases, and perforation was the major local complication (47.8%) in stromal tumors. Conclusion Primary small bowel cancers are usually diagnosed at advanced stages, and revealed by a local complication of the tumor. Their surgical management in emergency setting is associated to significant morbidity and mortality rates.


RESUMO Objetivo Caracterizar o padrão de neoplasias malignas primárias do intestino delgado em um hospital terciário de Leste Europeu. Métodos Estudo retrospectivo de pacientes com câncer de intestino delgado, internados em um hospital terciário e de emergência, ao longo dos últimos 15 anos. Resultados Foram avaliados 57 pacientes com neoplasias malignas gastrintestinais, o que representou 0,039% das admissões e 0,059% das laparotomias realizadas. Total de 37 (64,9%) pacientes masculinos, média de idade de 58 anos, e de 72 anos para mulheres. Dentre os 57 pacientes, 48 (84,2%) foram internados em situação de emergência: obstrução intestinal em 21 (38,9%), perfuração em 17 (31,5%), hemorragia digestiva alta em 8 (14,8%), e hemorragia digestiva baixa em 2 (3,7%). Houve 10 (17,5%) tumores duodenais, 21 (36,8%) jejunais e 26 (45,6%) ileais. As neoplasias mais frequentes foram tumor estromal gastrintestinal, em 24 (42,1%) pacientes, adenocarcinoma em 19 (33,3%), linfoma em 8 (14%) e carcinoides em 2 (3,5%). A prevalência de adenocarcinoma duodenal foi 14,55 vezes maior do que a do intestino delgado, e a prevalência de tumores estromais duodenais foi 1,818 vez maior do que a do intestino delgado. A obstrução intestinal foi complicação do adenocarcinoma em 57,9% dos casos, e a perfuração foi a principal complicação local (47,8%) dos tumores estromais. Conclusão As neoplasias malignas primárias do intestino delgado foram geralmente diagnosticadas em estado avançado e reveladas por uma complicação local do tumor. O tratamento cirúrgico em situação de emergência está associado à significativa morbimortalidade.


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Young Adult , Adenocarcinoma/complications , Carcinoid Tumor/complications , Gastrointestinal Hemorrhage/etiology , Gastrointestinal Stromal Tumors/complications , Intestinal Neoplasms/complications , Intestinal Obstruction/etiology , Intestinal Perforation/etiology , Adenocarcinoma/mortality , Adenocarcinoma/surgery , Carcinoid Tumor/mortality , Carcinoid Tumor/surgery , Duodenal Neoplasms/complications , Duodenal Neoplasms/mortality , Duodenal Neoplasms/surgery , Europe, Eastern , Emergency Medical Services/statistics & numerical data , Gastrointestinal Stromal Tumors/mortality , Gastrointestinal Stromal Tumors/surgery , Incidental Findings , Ileal Neoplasms/complications , Ileal Neoplasms/mortality , Ileal Neoplasms/surgery , Intestinal Neoplasms/mortality , Intestinal Neoplasms/surgery , Jejunal Neoplasms/complications , Jejunal Neoplasms/mortality , Jejunal Neoplasms/surgery , Lymphoma/complications , Lymphoma/mortality , Lymphoma/surgery , Patient Admission , Prevalence , Retrospective Studies , Tertiary Care Centers/statistics & numerical data
14.
J. pediatr. (Rio J.) ; 89(6): 595-600, nov.-dez. 2013. tab
Article in Portuguese | LILACS | ID: lil-697135

ABSTRACT

OBJETIVOS: a massagem é uma intervenção que pode contribuir para o alívio da dor, embora as evidências empíricas sejam escassas e contraditórias. O objetivo deste trabalho foi avaliar a eficácia de um protocolo de massagem no alívio da dor na criança internada, com patologia oncológica. MÉTODOS: através de um estudo randomizado e controlado com cegamento simples, foram estudadas 52 crianças, com idades compreendidas entre os 10 e os 18 anos, internadas num serviço de oncologia pediátrica. A intervenção consistiu na aplicação de um protocolo de massagem de três sessões com duração entre 20 a 30 minutos em dias alternados durante uma semana. A eficácia do protocolo foi medida através da avaliação da dor com a aplicação do Inventário Resumido de Dor e a eficácia de cada sessão de massagem pela Escala Visual Analógica (EVA). RESULTADOS: o protocolo de massagem apenas se revelou eficaz na diminuição da interferência da dor no andar (p < 0,05), apesar de ter contribuído para o alívio da dor e sua interferência nas atividades da criança. Após cada sessão de massagem a intensidade da dor sentida pela criança diminuiu (p < 0,001). CONCLUSÕES: apesar da reduzida dimensão da amostra, a massagem parece ser uma intervenção útil no alívio da dor da criança que sofre de patologia oncológica, embora permaneçam dúvidas quanto à eficácia deste protocolo de massagem. Todavia, os autores recomendam a sua utilização pela sua contribuição na promoção do bem-estar e qualidade de vida da criança.


OBJECTIVES: massage can help relieve pain, although empirical evidence is scarce and contradictory. This study aims to assess the effectiveness of a massage protocol in relieving pain in children hospitalized with cancer. METHODS: a randomized, controlled, and single-blind trial was performed in a sample of 52 children aged between 10 and 18 years who were hospitalized in a pediatric cancer ward. The intervention consisted of the implementation of a massage protocol with three sessions of 20 to 30 minutes on alternate days over a one-week period. The effectiveness of the protocol was evaluated by assessing pain using the Brief Pain Inventory (BPI), while the effectiveness of each massage session was measured using the Visual Analogue Scale (VAS). RESULTS: the massage protocol was only effective in reducing the interference of pain in walking (p < 0.05), although it also contributed to relieve pain and its impact on the children's activities. After each massage session, the intensity of the pain experienced by the child decreased (p < 0.001). CONCLUSIONS: despite the small sample size, massage therapy appears to be a useful intervention in reducing pain in children with cancer. However, there are still questions regarding the effectiveness of this massage protocol. The authors recommend its use due to its contribution to the promotion of the child's well-being and quality of life.


Subject(s)
Adolescent , Child , Humans , Massage , Neoplasms/complications , Pain Management/methods , Pain/etiology , Hospitalization , Leukemia/complications , Leukemia/therapy , Lymphoma/complications , Lymphoma/therapy , Pain Measurement , Prospective Studies , Single-Blind Method , Sarcoma/complications , Sarcoma/therapy , Treatment Outcome , Visual Analog Scale
15.
Rev. méd. Chile ; 141(11): 1475-1479, nov. 2013. ilus, tab
Article in Spanish | LILACS | ID: lil-704574

ABSTRACT

Secondary hemophagocytic syndrome (HFS) is an uncommon entity with a high mortality rate in adults, if no therapy is given. It is characterized by a severehipercytokinemia due to a highly stimulated but ineffective immune system. Theprincipal causes are infections, malignancy or autoimmune diseases. It appears asa serious illness, similar to a multiorgan failure. Treatment is not well defined. Wereport five patients with HFS, aged 17 to 51 years (three females). The etiology wasonco-hematological in three patients. In two patients, the diagnosis was performedduring necropsy. One case was due to cytomegalovirus (CMV) infection in a hepatictransplant patient and the other, due to parenteral lipid administration. All presentedfever, cytopenia, hepatosplenomegaly and hemophagocytosis. Four of them requiredadmission in an Intensive Care Unit. All received different treatment modalities. Onlyone survived. Median survival time was 75 days. In conclusion, HFS has differentetiologies and a high mortality in adults.


Subject(s)
Adolescent , Adult , Female , Humans , Male , Middle Aged , Young Adult , Cytomegalovirus Infections/complications , Lipids/adverse effects , Lymphohistiocytosis, Hemophagocytic/etiology , Lymphoma/complications , Parenteral Nutrition Solutions/adverse effects , Fatal Outcome , Intensive Care Units
16.
Annals of Laboratory Medicine ; : 145-149, 2013.
Article in English | WPRIM | ID: wpr-216007

ABSTRACT

Rothia mucilaginosa is a gram-positive coccus of the family Micrococcaceae. R. mucilaginosa is considered a part of the normal flora of the human oropharynx and upper respiratory tract and lower respiratory tract infections attributable to R. mucilaginosa are not frequent. We present a case of pneumonia, in which the R. mucilaginosa infection was diagnosed by quantitative cultures of a bronchoalveolar lavage (BAL) specimen. A 46-yr-old woman with B lymphoblastic lymphoma was admitted to the hospital for scheduled chemotherapy. Her chest computed tomography (CT) scan revealed bilateral multifocal nodular and patchy consolidation in both lungs. Investigation of the BAL specimen revealed that 7% of leukocytes had intracellular gram-positive cocci. The quantitative cultures of the BAL specimen grew mucoid, non-hemolytic, and grayish convex colonies on blood agar at a count of approximately 200,000 colony-forming units/mL. The colonies were identified as R. mucilaginosa. The patient was empirically treated with levofloxacin for 7 days, after which findings on the chest radiograph and CT scan improved. She was discharged with improvement on hospital day 46. To our knowledge, this is the first report of R. mucilaginosa pneumonia diagnosed in Korea. Quantitative culture of BAL specimen and examination of intracellular organisms are crucial for assessing the clinical significance of R. mucilaginosa recovered from the lower respiratory tract.


Subject(s)
Female , Humans , Middle Aged , Bronchoalveolar Lavage Fluid/microbiology , Lung/diagnostic imaging , Lymphoma/complications , Micrococcaceae/isolation & purification , Pneumonia/complications , Tomography, X-Ray Computed
17.
Article in English | IMSEAR | ID: sea-140111

ABSTRACT

The aim of this paper is to review the literature and identify orofacial manifestations of hematological diseases with special reference to hemato-oncologic, immuno-deficiency disorders, and human immunodeficiency virus infection. A computerized literature search using MEDLINE was conducted for published articles on orofacial manifestations of hematological diseases with emphasis on hemato-oncologic and human immunodeficiency virus (HIV) infection. Mesh phrases used in the search were: Oral diseases AND hematological disorders; orofacial diseases AND leukemias; orofacial lesions AND lymphomas; orofacial diseases AND multiple myeloma, orofacial manifestations AND HIV. The Boolean operator "AND" was used to combine and narrow the searches. The full texts of these articles were thoroughly examined. References in these articles also were manually searched non-Medline articles. Only relevant articles were selected for the review. Orofacial manifestation of malignant hematological diseases may present as primary clinical features due to infiltration of orofacial tissues, or as secondary due to the subsequent infiltration of normal bone marrow elements, or tertiary due to the side effects of the treatment. HIV-associated orofacial lesion may be a clinical indicator of HIV infection in otherwise healthy, undiagnosed individuals; an early clinical feature of HIV infection; clinical markers for the classification and staging of HIV disease or may be a predictor of HIV disease progression. Orofacial manifestations of malignant hematological diseases and HIV infection are not uncommon findings in clinical practice. These manifestations may be clinical indicators of hematologic disorders in otherwise healthy, undiagnosed individuals.


Subject(s)
HIV Infections/complications , Hematologic Diseases/complications , Hematologic Neoplasms/complications , Humans , Immunologic Deficiency Syndromes/complications , Leukemia/complications , Lymphoma/complications , Mouth Diseases/etiology , Myelodysplastic-Myeloproliferative Diseases/complications , Neoplasms, Plasma Cell/complications
18.
Rev. obstet. ginecol. Venezuela ; 71(1): 34-38, mar. 2011. tab
Article in Spanish | LILACS | ID: lil-631450

ABSTRACT

Evaluar el potencial que tiene la utilización de los análogos de GnRH en la conservación de la función ovárica a mediano y largo plazo en pacientes sometidas a quimioterapia. Se evaluó la recuperación de la función ovárica de 6 pacientes sometidas a tratamiento oncológico que fueron tratadas concomitantemente con análogo de GnRH, mediante la medición de FSH, estradiol sérico y presencia de menstruaciones. En la Clínica Santa Sofía y Salud Chacao, Caracas. Cinco de las seis pacientes evaluadas (83,3 por ciento), recuperaron su función ovárica posterior al tratamiento oncológico y con análogo de GnRH. El uso de análogos de GnRH durante el tratamiento médico oncológico pareciera ser una alternativa válida para la protección de la función ovárica


To evaluate the potential of GnRH analogs use during chemotherapy in the preservation of short and long term ovarian function. Evaluation of ovarian function by measuring FSH, seric estradiol and menses, in six patient after use of GnRH analogs during chemotherapy. Clinica Santa Sofia y Salud Chacao, Caracas. Five of six patients (83,3 percent) reassumed their ovarian function after chemotherapy plus GnRH analog. The use of GnRH seems to be a good alternative to protect ovary function during chemotherapy


Subject(s)
Female , Fertility , Gonadotropins, Pituitary/agonists , Gonadotropin-Releasing Hormone , Lymphoma/complications , Drug Therapy/adverse effects
19.
Archives of Iranian Medicine. 2011; 14 (4): 288-289
in English | IMEMR | ID: emr-129718

ABSTRACT

Hepatic granuloma is reported in 2 - 15% of liver biopsy specimens. It is relatively easy for the pathologist to diagnose, but sometimes arriving at a specific etiology is quite difficult. Until now, there are few published studies about the etiology of hepatic granuloma in Iran. In this study, we attempt to determine the causes of hepatic granuloma from one of the largest referral centers in this country. In a retrospective study over 12 years, a hepatopathologist reviewed all liver biopsies with granuloma. The medical records, including clinical findings, autoantibodies, viral markers, imaging studies, drug histories, and all other specialized tests, such as molecular studies, were reviewed to reach a definite diagnosis. During 12 years, there were 72 cases diagnosed with liver granuloma. The most common cause of hepatic granuloma was infectious, with Mycobacterium tuberculosis [52.8%]. The second most common cause was visceral leishmaniasis in 8.3% of biopsies. Other less common causes were fungal infections, visceral larva migrans, primary biliary cirrhosis, and hepatitis C, each in 4.2% of cases. Autoimmune hepatitis was diagnosed in 2.8% of patients. Lymphoma, drug induced, disseminated BCGitis, CMV infection, foreign body reaction and sarcoidosis, were each found in 1.4% of the liver biopsies. After all investigations, there were 12.5% idiopathic hepatic granulomas. According to this study, the most common cause of hepatic granuloma in Iran is tuberculosis. This finding is completely different from western countries and very similar to the results of countries such as Saudi Arabia


Subject(s)
Humans , Male , Female , Young Adult , Infant, Newborn , Infant , Child, Preschool , Child , Adolescent , Adult , Middle Aged , Liver Diseases/etiology , Hepatitis C/complications , Hepatitis, Autoimmune/complications , Granuloma, Foreign-Body/etiology , Coronavirus Infections/complications , Larva Migrans, Visceral/complications , Leishmaniasis, Visceral/complications , Liver Cirrhosis, Biliary/complications , Lymphoma/complications , Tuberculosis, Hepatic/complications
20.
Iranian Journal of Veterinary Research. 2009; 10 (1[26]): 81-83
in English | IMEMR | ID: emr-91392

ABSTRACT

Postmortem examination of a 5.5-year-old Holstein cow with history of sudden death showed a very huge spleen [120 x 45 x 10 cm] associated with severe haemoperitoneum. Histopathological findings included extensive infiltration of medium to large sized lymphocytic and lymphoblastic cells with small amounts of cytoplasm, round nuclei with coarsely granular chromatin in the spleen, and limited foci of similar cellular infiltration in the liver. This case was diagnosed as a fatal splenic rupture caused by an atypical malignant lymphoma


Subject(s)
Animals , Splenic Rupture/etiology , Lymphoma/complications , Cattle , Hemoperitoneum , Death, Sudden
SELECTION OF CITATIONS
SEARCH DETAIL